LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-19
Case ID: NM_001904.4_c.2009A_G_20261119_203411
Framework: ACMG/AMP 2015
Variant classification summary

NM_001904.4:c.2009A>G

CTNNB1  · NP_001895.1:p.(Tyr670Cys)  · NM_001904.4
GRCh37: chr3:41278133 A>G  ·  GRCh38: chr3:41236642 A>G
Gene: CTNNB1 Transcript: NM_001904.4
Final call
VUS
PM2 moderate BP1 supporting
All criteria require review: For research and educational purposes only.
Gene
CTNNB1
Transcript
NM_001904.4
Protein
NP_001895.1:p.(Tyr670Cys)
gnomAD AF
ClinVar
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PM2 moderate: the variant is absent from gnomAD v2.1 and v4.1, below the generic 0.01% threshold.
2
BP1 supporting: CTNNB1 cohorts include 118 truncating versus 4 missense variants, indicating a predominantly truncating disease mechanism.
Final determination: Under generic ACMG/AMP 2015 rules, one moderate pathogenic criterion plus one supporting benign-direction criterion satisfies neither a pathogenic nor a benign combination, so the call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PS1 Not assessed Not assessed: no verified pathogenic variant producing the same CTNNB1 Tyr670Cys amino-acid change was identified.
PMID:36153650 PMID:40684264
PS2 Not assessed Not assessed: no proband phenotype, family-history status, or confirmed maternity and paternity testing is documented for this variant.
PS3 Not assessed Not assessed: functional studies tested Y670F/Y670E or other CTNNB1 variants, not the c.2009A>G (p.Tyr670Cys) substitution.
PMID:16952352 PMID:21423209 PMID:40684264
PS4 Not assessed Not assessed: no exact-variant case-control counts or prevalence comparison were available to calculate the required OR/RR and 95% confidence interval.
PMID:36153650 PMID:40684264 gnomad_v2 gnomad_v4 gnomad_canada
PM1 Not met Not met: Y670 has functional importance, but no qualifying critical domain or statistically significant hotspot was established, and COSMIC reports only one occurrence.
PMID:16952352 PMID:21423209 hotspots cosmic
PM2 Met Met, Moderate: the variant was absent from gnomAD v2.1 and v4.1, below the <=0.01% PM2 threshold.
gnomad_v2 gnomad_v4 generic_acmg_combination_rules
PM3 N/A Not applicable: CTNNB1 neurodevelopmental disorder is described as autosomal dominant with heterozygous variants, whereas PM3 is restricted to recessive disorders.
PMID:36153650
PM4 N/A Not applicable: PM4 requires a protein-length change, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PM5 Not assessed Not assessed: experimental Y670 substitutions were reported, but no different pathogenic missense change at Tyr670 was verified.
PMID:16952352 PMID:21423209 PMID:40684264 pm5_candidates
PM6 Not assessed Not assessed: no assumed de novo occurrence or parental genotype data are documented for this variant.
PP1 Not assessed Not assessed: zero affected relatives or informative co-segregation meioses are documented for this variant.
PP2 Not met Not met: CTNNB1 disease cohorts show 118 truncating versus 4 missense variants, with a PTC:missense ratio of 29.5 rather than a common missense mechanism.
PMID:40684264 PMID:36153650
PP3 Not met Not met: missense REVEL score 0.44 is below the PP3 supporting threshold of >= 0.644.
revel
PP4 Not assessed Not assessed: no case-specific phenotype or family history was available to show a highly specific CTNNB1 disease presentation.
PMID:36153650 PMID:40684264
PP5 Not met Not met: ClinVar has no exact-variant record, expert-panel submission, or qualifying pathogenic assertion for NM_001904.4:c.2009A>G.
BA1 Not met Not met: the variant was absent from gnomAD v2.1 and v4.1, far below the 5% BA1 threshold.
gnomad_v2 gnomad_v4 generic_acmg_combination_rules
BS1 Not met Not met: gnomAD reported no observed alleles, so filtering allele frequency is 0 and below the generic 1% BS1 threshold.
gnomad_v2 gnomad_v4 generic_acmg_combination_rules
BS2 Not assessed Not assessed: no healthy adult carrying the variant with the required zygosity and early-onset full-penetrance context was documented.
BS3 Not assessed Not assessed: no validated assay directly showed that p.Tyr670Cys has no damaging effect on CTNNB1 protein function or splicing.
PMID:16952352 PMID:21423209 PMID:40684264
BS4 Not assessed Not assessed: no affected relatives with documented absence of the variant are reported.
BP1 Met Met, supporting: CTNNB1 disease data include 118 truncating versus 4 missense variants, a PTC:missense ratio of 29.5.
PMID:40684264 PMID:36153650
BP2 Not assessed Not assessed: no affected-proband observation or phase testing establishes this variant in trans or cis with a pathogenic variant.
BP3 N/A Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
BP4 Not met Not met: missense REVEL score 0.44 is above the BP4 supporting threshold of <= 0.29.
revel
BP5 Not met Not met: no clinical case documents this variant alongside an alternate molecular basis for the disease; the single COSMIC somatic entry is insufficient.
cosmic
BP6 Not met Not met: ClinVar has no exact-variant record, expert-panel submission, or qualifying benign assertion for NM_001904.4:c.2009A>G.
BP7 N/A Not applicable: BP7 requires a synonymous variant, and this is a missense variant.
generic_acmg_combination_rules
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.